Fuse Vectors secures $5.2m to advance cell-free gene therapy technology, led by HCVC

Danish biotech replaces cell-based methods with revolutionary cell-free technology, making gene therapy more accessible

28-Feb-2025 - Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck in the 1980s, relying on unpredictable cell-based methods that make therapies costly and slow to develop. Today, Fuse Vectors announces $5.2 ...

ProBioGen expands protein and virus manufacturing to drive continued growth

09-Jan-2025 - ProBioGen announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.In the protein ...

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million

"This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"

24-May-2024 - Merck has signed a definitive agreement to acquire life science company Mirus Bio for US$600million (around €550million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio's ...

Merck Invests More Than € 300 Million in New Life Science Research Center in Germany

Research center to accelerate biopharmaceutical product development

26-Apr-2024 - Merck, a leading science and technology company, is investing more than €300 million in a new research center at its global headquarters in Darmstadt, Germany. In the Advanced Research Center, the Life Science business sector will research solutions for manufacturing antibodies, mRNA ...

NewBiologix Launches with $50M to Advance Novel Technology Platform for the Manufacturing of Gene and Cell Therapies

Co-founded by cell line development pioneers, Igor Fisch and Nicolas Mermod

17-May-2023 - NewBiologix SA emerged from stealth as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The Company’s DNA-based platform is being developed to address key manufacturing ...

Sartorius acquires French provider of innovative upstream technologies for cell and gene therapies

Agreed purchase price of approximately 2.4 billion euros

03-Apr-2023 - The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has signed an agreement to acquire Polyplus for approximately 2.4 billion euros from private investors including ARCHIMED and WP GG Holdings IV B.V., an affiliate of Warburg Pincus. Polyplus, with ...

Merck and Japanese start-up launch collaboration

Both companies to accelerate development and manufacturing of viral vector-based gene therapy applications

15-Dec-2022 - Merck has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation. Both companies aim to integrate their capabilities to provide streamlined development, manufacturing and testing for ...

New gene taxis to combat liver disease

Research team finds two promising AAV capsid variants for gene therapy in the liver

31-Oct-2022 - There are numerous severe, hardly treatable monogenetic diseases that are caused by a defect in a single gene - also in the liver. These include the blood coagulation disorders haemophilia A or B or the metabolic disease phenylketonuria. Gene therapies could help here, in which intact genes are ...

PRIME’s technology for the development of novel veterinary vaccines

Boehringer Ingelheim and Biotech Startup enter a strategic collaboration

29-Nov-2021 - Prime Vector Technologies (PRIME), a Biotech Startup focusing on the development of viral vector based vaccines, and Boehringer Ingelheim, a leading global research-based pharmaceutical company, announce that they have entered a strategic collaboration, option and licence agreement. The ...

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Growth through investments in the “Big 3”

13-Oct-2021 - Merck announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint. This new €100 million, 140,000-square foot facility will more than double the company’s existing capacity to support large-scale commercial and industrial ...